Company / R&D Expense
Evolent Health, Inc. R&D Expense History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$15.5M
FY2021
5-year range
$15.5M / $15.5M
FY2017-FY2021
Trend
+2.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $20M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2021 with a 5-year CAGR of +6.9%.
Declined from $20M to $16M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -5.2%
- 5-Year CAGR
- +6.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.9%, indicating consistent growth.
- In FY2021, r&d expense increased 2.6% year-over-year.
- Peak r&d expense was recorded in FY2019.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $15.5M | +2.6% |
| FY2020 | $15.1M | -23.7% |
| FY2019 | $19.8M | +8.8% |
| FY2018 | $18.2M | +5.8% |
| FY2017 | $17.2M | +55.0% |
| FY2016 | $11.1M | +91.4% |
As of FY2021 · SEC Form 10-K · Last checked Jun 21, 2026